PLIANT THERAPT (PLRX)
(Real Time Quote from BATS)
$1.66 USD
-0.07 (-4.05%)
Updated Aug 6, 2025 12:54 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PLRX 1.66 -0.07(-4.05%)
Will PLRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PLRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLRX
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
PLRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
Other News for PLRX
From Nebius Group To EOS: A Strong Year And What's Next For Our Family Office
12 Health Care Stocks Moving In Friday's After-Market Session
Pliant Therapeutics (PLRX) Halts Development of Key Drug After Trial Setback
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock News